Thrombotic microangiopathy (TMA) is a severe complication of kidney transplantation that
often causes graft failure. TMA may occur de novo, often triggered by immunosuppressive …

Central to the pathogenesis of atypical hemolytic uremic syndrome (aHUS) is over-activation
of the alternative pathway of complement. Following the initial discovery of mutations in the …

Background and objectives: Hemolytic uremic syndrome (HUS) is characterized by
microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment. Most …

In contrast to pregnancy-associated thrombotic thrombocytopenic purpura, the pathogenesis
and presentation of pregnancy-associated atypical hemolytic uremic syndrome (P-aHUS) …

Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy
that associates, in 70% of cases, with genetic or acquired disorders leading to dysregulation …

Genetic studies have shown that mutations of complement inhibitors such as membrane
cofactor protein, Factors H, I, or B and C3 predispose patients to atypical hemolytic uremic …

Plasmatherapy has become empirically first-line treatment in atypical hemolytic uremic
syndrome (aHUS), although no prospective controlled trials have been conducted. Patients …

To the Editor: Atypical hemolytic–uremic syndrome is a rare microangiopathic hemolytic
condition characterized by thrombocytopenia and acute renal failure. 1 The prognosis for …

Abstract Background. Atypical HUS (aHUS) is thought to be caused by predisposing
mutations in genes encoding complement (regulating) proteins, such as Factor H (CFH) …

Atypical hemolytic uremic syndrome (aHUS) is a rare disease of microangiopathic hemolytic
anemia, thrombocytopenia, and predominant renal impairment. It is characterized by the …